Skip to contentC
Collegium Pharmaceutical, Inc
C
COLLCollegium Pharmaceutical, Inc Q4 2020 · 10-K
Revenue$76.27M$76.27M+2.8% vs Q4 2019 Net Income$6.96M$6.96MN/M vs Q4 2019 EPS Diluted$0.20$0.20N/M vs Q4 2019 Gross Profit$44,292,000+76.4% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Collegium Pharmaceutical, Inc · CIK 1267565 · Engraved from SEC EDGAR
Operating Cash Flowderived$22,577,000+44.2% Free Cash Flowderived$21,096,000+42.9% Margins · derivedGross margin58.1%+24.2 pt vs Q4 2019
Operating margin19.7%+22.9 pt vs Q4 2019
Net margin9.1%+12.1 pt vs Q4 2019
ended Dec 31, 2020 · filed Feb 25, 2021 · 56 d after period end